As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

It’s similar with multiple sclerosis. Actually, there are so many good drugs out there. A lot of the market has already been ...

Sima Sistani, CEO of WeightWatchers, announced her departure from the weight-loss company, which has struggled to adapt in ...

BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A woman from Chester Springs, Pennsylvania, is one of the first patients in the country to receive a new FDA-approved ...

The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...

In the 1990s, Eli Lilly researched a molecule called xanomeline for Alzheimer’s disease and found that it had potent ...